IOVANCE BIOTHERAPEUTICS, INC. Cost of Revenue
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) reported Cost of Revenue of $43.59 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement
us-gaap:CostOfRevenue · last filed 2026-08-06
- IOVANCE BIOTHERAPEUTICS, INC. cost of revenue for the quarter ending 2026-06-30 was $43.59M, a 10.81% decline year-over-year.
- IOVANCE BIOTHERAPEUTICS, INC. cost of revenue for the quarter ending 2026-03-31 was $42.50M, a 0.51% decline year-over-year.
- IOVANCE BIOTHERAPEUTICS, INC. cost of revenue for the quarter ending 2025-12-31 was $43.11M, a 14.08% increase year-over-year.
- IOVANCE BIOTHERAPEUTICS, INC. cost of revenue for the quarter ending 2025-09-30 was $38.48M, a 22.08% increase year-over-year.
- IOVANCE BIOTHERAPEUTICS, INC. cost of revenue for fiscal 2025 was $173.18M, a 85.72% increase from fiscal 2024.
- IOVANCE BIOTHERAPEUTICS, INC. cost of revenue for fiscal 2024 was $93.25M, a 8926.91% increase from fiscal 2023.
- IOVANCE BIOTHERAPEUTICS, INC. cost of revenue for fiscal 2023 was $1.03M.
| Period end | Cost of Revenue 3 month | Cost of Revenue 3 month as first filed | Cost of Revenue 6 month | Cost of Revenue 6 month as first filed | Cost of Revenue 9 month | Cost of Revenue 9 month as first filed | Cost of Revenue 12 month | Cost of Revenue 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $43.59M 10-Q · filed 2026-08-06 | $86.09M 10-Q · filed 2026-08-06 | $129.20M derived: sum of 3 quarters · filed 2026-08-06 | $167.68M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2026-03-31 | $42.50M 10-Q · filed 2026-05-07 | $85.61M derived: sum of 2 quarters · filed 2026-05-07 | $124.09M derived: sum of 3 quarters · filed 2026-05-07 | $172.97M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-12-31 | $43.11M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $81.59M derived: sum of 2 quarters · filed 2026-02-24 | $130.47M derived: sum of 3 quarters · filed 2026-08-06 | $173.18M 10-K · filed 2026-02-24 | ||||
| 2025-09-30 | $38.48M 10-Q · filed 2025-11-06 | $87.36M derived: sum of 2 quarters · filed 2026-08-06 | $130.07M 10-Q · filed 2025-11-06 | $167.86M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-06-30 | $48.88M 10-Q · filed 2026-08-06 | $56.66M 10-Q · filed 2025-08-07 | $91.59M 10-Q · filed 2026-08-06 | $106.41M 10-Q · filed 2025-08-07 | $129.38M derived: sum of 3 quarters · filed 2026-08-06 | $160.90M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-03-31 | $42.72M 10-Q · filed 2026-05-07 | $49.74M 10-Q · filed 2025-05-08 | $80.50M derived: sum of 2 quarters · filed 2026-05-07 | $112.02M derived: sum of 3 quarters · filed 2026-05-07 | $143.39M derived: sum of 4 quarters · filed 2026-05-07 | |||
| 2024-12-31 | $37.79M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $69.31M derived: sum of 2 quarters · filed 2026-02-24 | $100.67M derived: sum of 3 quarters · filed 2026-02-24 | $93.25M 10-K · filed 2026-02-24 | $124.00M 10-K · filed 2025-02-27 | |||
| 2024-09-30 | $31.52M 10-Q · filed 2025-11-06 | $39.82M 10-Q · filed 2024-11-07 | $62.89M derived: sum of 2 quarters · filed 2025-11-06 | $55.46M 10-Q · filed 2025-11-06 | $78.45M 10-Q · filed 2024-11-07 | $64.79M derived: sum of 4 quarters · filed 2026-02-24 | ||
| 2024-06-30 | $31.37M 10-Q · filed 2025-08-07 | $38.63M 10-Q · filed 2025-08-07 | $33.27M derived: sum of 3 quarters · filed 2026-02-24 | $37.61M derived: sum of 4 quarters · filed 2026-02-24 | ||||
| 2024-03-31 | $7.26M 10-Q · filed 2025-05-08 | $1.90M derived: sum of 2 quarters · filed 2026-02-24 | $6.24M derived: sum of 3 quarters · filed 2026-02-24 | $8.29M derived: sum of 4 quarters · filed 2026-02-24 | ||||
| 2023-12-31 | -$5.36M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$1.02M derived: sum of 2 quarters · filed 2026-02-24 | $1.03M derived: sum of 3 quarters · filed 2026-02-24 | $1.03M 10-K · filed 2026-02-24 | $10.76M 10-K · filed 2024-02-28 | |||
| 2023-09-30 | $4.34M 10-Q · filed 2024-11-07 | $6.39M derived: sum of 2 quarters · filed 2024-11-07 | $6.39M 10-Q · filed 2024-11-07 | |||||
| 2023-06-30 | $2.05M 10-Q · filed 2024-08-08 | $2.05M 10-Q · filed 2024-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |